Danaher, a science and technology company, has agreed to acquire biotech firm Aldevron from EQT Private Equity for an enterprise value of $9.bn.
Established in 1998, Aldevron is headquartered in Fargo, North Dakota, US. The company produces plasmid DNA, mRNA and recombinant proteins used in vaccines, gene and cell therapy, gene editing and diagnostic applications.
Aldevron offers its products to biotechnology and pharmaceutical clients for research, clinical and commercial purposes. It supplied the plasmid DNA utilised to produce mRNA Covid-19 vaccines, EQT noted.
EQT purchased a majority stake in Aldevron in 2019, investing along with TA Associates, founders and management to aid the biotech in developing biologics.